Latest rectal cancer Stories
Enables physicians to pursue more effective treatment plans for patients who are chemoradiation resistant CHICAGO, May 6, 2014 /PRNewswire/ -- Castle Biosciences Inc.
A study presented at the Society of Nuclear Medicine's 2012 Annual Meeting reveals how molecular imaging biomarkers can be used to approximate howan experimental radiochemotherapy for locally advanced rectal cancer will work.
Research from the University of Alberta provides new insight into treatment patterns for people with stage two and three rectal cancer—information that ultimately will help physicians improve care strategies for patients provincewide.
Specific fruits and veggies reduce risks of Colorectal Cancer (CRC), some veggies help prevent proximal and distal, while others just help to prevent distal CRC.
Rectal cancer patients who use a new combination of the chemotherapy, Capecitabine, together with five weeks of radiation (50 Gy) before surgery have an 88 percent chance of surviving the cancer three years after treatment.
The effects of fruit and vegetable consumption on colorectal cancer (CRC) appear to differ by site of origin.
First results from an international comparison of the care of patients with rectal cancer have shown there are substantial differences in the use of chemotherapy and radiotherapy between European countries.
A new study has shown that magnetic resonance imaging (MRI) used to evaluate responses to pre-surgery (neo-adjuvant) chemotherapy or radiation may predict survival among patients with advanced rectal cancer.
Patients with cancer found at the end of the large intestine called the rectum who receive one week of radiation therapy before surgery have a 50 percent reduction in chance that their cancer will return after 10 years.